PA
CRDF icon

Parallel Advisors’s Cardiff Oncology CRDF Stock Holding History

Parallel Advisors’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46 Buy
+35
New +$56 ﹤0.01% 3894
2025
Q4 		– Sell
-1,000
Closed -$2.06K – 3646
2025
Q3 		$2.06K Hold
1,000
– – ﹤0.01% 3043
2025
Q2 		$3.15K Hold
1,000
– – ﹤0.01% 2903
2025
Q1 		$3.14K Buy
+1,000
New +$3.96K ﹤0.01% 2838
2017
Q1 		– Sell
-2
Closed – – 1994
2016
Q4 		$0 Buy
+2
New +$467 ﹤0.01% 1769

Other funds holding CRDF

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AC
Avestar Capital New York $1.79B AUM 33.8% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return

Parallel Advisors's CRDF Position: Q2 2026 in Review

Parallel Advisors opened a new position in Cardiff Oncology (CRDF) in Q2 2026: 35 shares worth $46. The stake represents ﹤0.01% of the portfolio and ranks #3894 among its holdings. This is a return to the name: Parallel Advisors previously reported a position in CRDF as recently as Q3 2025.

Parallel Advisors first reported a position in CRDF in Q4 2016 and has held it in 5 quarters since. The position peaked at $3.15K in Q2 2025. 40 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • Parallel Advisors held 35 shares of Cardiff Oncology worth $46 as of Q2 2026.
  • Cardiff Oncology was a new Parallel Advisors position in Q2 2026.
  • Cardiff Oncology made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3894 holding.
  • Parallel Advisors first reported a position in Cardiff Oncology in Q4 2016 and has held it in 5 quarters since.
  • Parallel Advisors's Cardiff Oncology position peaked at $3.15K in Q2 2025.
  • 40 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.